Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Immunotherapy: New Options in Gastrointestinal Cancers?

Tannapfel A, Reinacher-Schick A, Hacker U, Lorenzen S, Möhler M, Vogel A.

Visc Med. 2019 Mar;35(1):47-51. doi: 10.1159/000497293. Epub 2019 Feb 14. No abstract available.

PMID:
31312650
2.

Immunotherapy in Gastrointestinal Cancer: Where Do We Stand?

Tannapfel A, Reinacher-Schick A.

Visc Med. 2019 Mar;35(1):1-2. doi: 10.1159/000497294. Epub 2019 Feb 8. No abstract available.

3.

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL.

N Engl J Med. 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387. Epub 2019 Jun 2.

PMID:
31157963
4.

A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer.

Berger AW, Schwerdel D, Reinacher-Schick A, Uhl W, Algül H, Friess H, Janssen KP, König A, Ghadimi M, Gallmeier E, Bartsch DK, Geissler M, Staib L, Tannapfel A, Kleger A, Beutel A, Schulte LA, Kornmann M, Ettrich TJ, Seufferlein T.

Theranostics. 2019 Feb 12;9(5):1280-1287. doi: 10.7150/thno.29247. eCollection 2019.

5.

Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.

Ettrich TJ, Berger AW, Perkhofer L, Daum S, König A, Dickhut A, Wittel U, Wille K, Geissler M, Algül H, Gallmeier E, Atzpodien J, Kornmann M, Muche R, Prasnikar N, Tannapfel A, Reinacher-Schick A, Uhl W, Seufferlein T.

BMC Cancer. 2018 Dec 29;18(1):1298. doi: 10.1186/s12885-018-5183-y.

6.

Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial.

Stintzing S, Ivanova B, Ricard I, Jung A, Kirchner T, Tannapfel A, Juette H, Hegewisch-Becker S, Arnold D, Reinacher-Schick A.

Front Oncol. 2018 Nov 8;8:474. doi: 10.3389/fonc.2018.00474. eCollection 2018.

7.

Prospective Study of the Clinical, Electrophysiologic, and Sonographic Characteristics of Oxaliplatin-Induced Neuropathy.

Pitarokoili K, Höffken N, Lönneker N, Fisse AL, Trampe N, Gold R, Reinacher-Schick A, Yoon MS.

J Neuroimaging. 2019 Jan;29(1):133-139. doi: 10.1111/jon.12557. Epub 2018 Sep 10.

PMID:
30198601
8.

"I need to know what makes somebody tick …": Challenges and Strategies of Implementing Shared Decision-Making in Individualized Oncology.

Haltaufderheide J, Wäscher S, Bertlich B, Vollmann J, Reinacher-Schick A, Schildmann J.

Oncologist. 2019 Apr;24(4):555-562. doi: 10.1634/theoncologist.2017-0615. Epub 2018 Sep 6.

PMID:
30190300
9.

Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial.

Noepel-Duennebacke S, Arnold D, Hertel J, Tannapfel A, Hinke A, Hegewisch-Becker S, Reinacher-Schick A.

Clin Colorectal Cancer. 2018 Dec;17(4):e733-e739. doi: 10.1016/j.clcc.2018.07.007. Epub 2018 Jul 25.

PMID:
30145148
10.

Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.

Hegewisch-Becker S, Nöpel-Dünnebacke S, Hinke A, Graeven U, Reinacher-Schick A, Hertel J, Lerchenmüller CA, Killing B, Depenbusch R, Al-Batran SE, Lange T, Dietrich G, Tannapfel A, Arnold D.

Eur J Cancer. 2018 Sep;101:105-113. doi: 10.1016/j.ejca.2018.06.015. Epub 2018 Jul 20.

PMID:
30036739
11.

Breakthrough treatment with bortezomib for a patient with anti-NMDAR encephalitis.

Schroeder C, Back C, Koc Ü, Strassburger-Krogias K, Reinacher-Schick A, Gold R, Haghikia A.

Clin Neurol Neurosurg. 2018 Sep;172:24-26. doi: 10.1016/j.clineuro.2018.06.005. Epub 2018 Jun 23.

PMID:
29960102
12.

FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer.

Luu AM, Herzog T, Hoehn P, Reinacher-Schick A, Munding J, Uhl W, Braumann C.

J Gastrointest Oncol. 2018 Apr;9(2):E9-E12. doi: 10.21037/jgo.2018.01.07.

13.

[ASCO- and ESMO-update 2017 - highlights of the 53. meeting of the American Society of Clinical Oncology/ASCO 2017 and European Society for Medical Oncology/ESMO congress 2017].

Ettrich TJ, Ebert M, Lorenzen S, Moehler M, Vogel A, Witkowski L, Seufferlein T, Reinacher-Schick A.

Z Gastroenterol. 2018 Apr;56(4):384-397. doi: 10.1055/s-0044-101757. Epub 2018 Apr 11. German.

PMID:
29642252
14.

Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.

Haas M, Siveke JT, Schenk M, Lerch MM, Caca K, Freiberg-Richter J, Fischer von Weikersthal L, Kullmann F, Reinacher-Schick A, Fuchs M, Kanzler S, Kunzmann V, Ettrich TJ, Kruger S, Westphalen CB, Held S, Heinemann V, Boeck S.

Eur J Cancer. 2018 May;94:95-103. doi: 10.1016/j.ejca.2018.02.008. Epub 2018 Mar 20.

PMID:
29549862
15.

[Physician perspectives on the impact of patient preferences and the role of next-of-kin of patients in evidence-based decision-making: A qualitative interview study from oncology].

Salloch S, Otte IC, Reinacher-Schick A, Vollmann J.

Z Evid Fortbild Qual Gesundhwes. 2018 Apr;131-132:46-52. doi: 10.1016/j.zefq.2018.02.002. Epub 2018 Mar 12. German.

PMID:
29544714
16.

Treatment recommendations within the leeway of clinical guidelines: A qualitative interview study on oncologists' clinical deliberation.

Otte I, Salloch S, Reinacher-Schick A, Vollmann J.

BMC Cancer. 2017 Nov 21;17(1):780. doi: 10.1186/s12885-017-3783-6.

17.

What does physicians' clinical expertise contribute to oncologic decision-making? A qualitative interview study.

Salloch S, Otte I, Reinacher-Schick A, Vollmann J.

J Eval Clin Pract. 2018 Feb;24(1):180-186. doi: 10.1111/jep.12840. Epub 2017 Oct 27.

PMID:
29076629
18.

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience.

Schneider-Gold C, Reinacher-Schick A, Ellrichmann G, Gold R.

Ther Adv Neurol Disord. 2017 Oct;10(10):339-341. doi: 10.1177/1756285617721093. Epub 2017 Jul 26. No abstract available.

19.

Severe refractory CIDP: a case series of 10 patients treated with bortezomib.

Pitarokoili K, Yoon MS, Kröger I, Reinacher-Schick A, Gold R, Schneider-Gold C.

J Neurol. 2017 Sep;264(9):2010-2020. doi: 10.1007/s00415-017-8599-4. Epub 2017 Aug 23.

PMID:
28836002
20.

Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer.

Herbst A, Vdovin N, Gacesa S, Ofner A, Philipp A, Nagel D, Holdt LM, Op den Winkel M, Heinemann V, Stieber P, Graeven U, Reinacher-Schick A, Arnold D, Ricard I, Mansmann U, Hegewisch-Becker S, Kolligs FT.

Int J Cancer. 2017 May 1;140(9):2134-2144. doi: 10.1002/ijc.30625. Epub 2017 Feb 22. Erratum in: Int J Cancer. 2018 Feb 1;142(3):E1.

21.

Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing.

Schmiegel W, Scott RJ, Dooley S, Lewis W, Meldrum CJ, Pockney P, Draganic B, Smith S, Hewitt C, Philimore H, Lucas A, Shi E, Namdarian K, Chan T, Acosta D, Ping-Chang S, Tannapfel A, Reinacher-Schick A, Uhl W, Teschendorf C, Wolters H, Stern J, Viebahn R, Friess H, Janssen KP, Nitsche U, Slotta-Huspenina J, Pohl M, Vangala D, Baraniskin A, Dockhorn-Dworniczak B, Hegewisch-Becker S, Ronga P, Edelstein DL, Jones FS, Hahn S, Fox SB.

Mol Oncol. 2017 Feb;11(2):208-219. doi: 10.1002/1878-0261.12023. Epub 2017 Jan 20.

22.

Amphiphysin-positive paraneoplastic myelitis and stiff-person syndrome.

Faissner S, Lukas C, Reinacher-Schick A, Tannapfel A, Gold R, Kleiter I.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 28;3(6):e285. eCollection 2016 Dec. No abstract available.

23.

Bortezomib Treatment for Patients With Anti-N-Methyl-d-Aspartate Receptor Encephalitis.

Behrendt V, Krogias C, Reinacher-Schick A, Gold R, Kleiter I.

JAMA Neurol. 2016 Oct 1;73(10):1251-1253. doi: 10.1001/jamaneurol.2016.2588. No abstract available.

PMID:
27533122
24.

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.

Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, Stintzing S, Graeven U, Arnold D, von Weikersthal LF, Giessen-Jung C, Stahler A, Schmoll HJ, Jung A, Kirchner T, Tannapfel A, Reinacher-Schick A.

Ann Oncol. 2016 Sep;27(9):1746-53. doi: 10.1093/annonc/mdw261. Epub 2016 Jun 29.

25.

[ASCO-update 2015 - highlights of the 51. meeting of the american society of clinical oncology/ASCO 2015].

Lorenzen S, Arnold D, Fottner C, Leichsenring J, Moehler M, Seufferlein T, Vogel A, Weber MM, Reinacher-Schick A.

Z Gastroenterol. 2016 Feb;54(2):167-72. doi: 10.1055/s-0041-111632. Epub 2016 Feb 8. German.

PMID:
26854837
26.

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.

Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Reinacher-Schick A, Quidde J, Trarbach T, Hinke A, Schmoll HJ, Arnold D.

Lancet Oncol. 2015 Oct;16(13):1355-69. doi: 10.1016/S1470-2045(15)00042-X. Epub 2015 Sep 8. Erratum in: Lancet Oncol. 2015 Dec;16(16):e589.

PMID:
26361971
27.

[Clinically relevant, gender-specific differences in colorectal carcinoma (CRC)].

Höffken N, Leichsenring J, Reinacher-Schick A.

Z Gastroenterol. 2015 Aug;53(8):782-8. doi: 10.1055/s-0035-1553476. Epub 2015 Aug 18. Review. German.

PMID:
26284326
28.

Multiple cerebral infarctions in a young patient with heroin-induced hypereosinophilic syndrome.

Bolz J, Meves SH, Kara K, Reinacher-Schick A, Gold R, Krogias C.

J Neurol Sci. 2015 Sep 15;356(1-2):193-5. doi: 10.1016/j.jns.2015.06.031. Epub 2015 Jun 16.

PMID:
26104570
29.

Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy.

Nöpel-Dünnebacke S, Schulmann K, Reinacher-Schick A, Porschen R, Schmiegel W, Tannapfel A, Graeven U.

Z Gastroenterol. 2014 Dec;52(12):1394-401. doi: 10.1055/s-0034-1366781. Epub 2014 Dec 4.

PMID:
25474278
30.

[Colorectal Carcinoma with Suspected Lynch Syndrome: A Multidisciplinary Algorithm].

Schneider R, Schneider C, Büttner R, Reinacher-Schick A, Tannapfel A, Fürst A, Rüschoff J, Jakobeit C, Royer-Pokora B, Möslein G.

Zentralbl Chir. 2015 Dec;140(6):591-9. doi: 10.1055/s-0034-1368480. Epub 2014 Nov 5. Review. German.

PMID:
25372301
31.

Colorectal Cancer: Personalized Therapy.

Leichsenring J, Koppelle A, Reinacher-Schick A.

Gastrointest Tumors. 2014 May;1(4):209-20. doi: 10.1159/000380790. Epub 2015 Apr 15. Review.

32.

Colorectal Adenoma - Resection Techniques and Surveillance.

Kähler G, Reinacher-Schick A.

Viszeralmedizin. 2014 Feb;30(1):8-9. doi: 10.1159/000360561. No abstract available.

33.

Label-free imaging of drug distribution and metabolism in colon cancer cells by Raman microscopy.

El-Mashtoly SF, Petersen D, Yosef HK, Mosig A, Reinacher-Schick A, Kötting C, Gerwert K.

Analyst. 2014 Mar 7;139(5):1155-61. doi: 10.1039/c3an01993d. Epub 2014 Jan 15.

PMID:
24427772
34.

[S3-guideline exocrine pancreatic cancer].

Seufferlein T, Porzner M, Becker T, Budach V, Ceyhan G, Esposito I, Fietkau R, Follmann M, Friess H, Galle P, Geissler M, Glanemann M, Gress T, Heinemann V, Hohenberger W, Hopt U, Izbicki J, Klar E, Kleeff J, Kopp I, Kullmann F, Langer T, Langrehr J, Lerch M, Löhr M, Lüttges J, Lutz M, Mayerle J, Michl P, Möller P, Molls M, Münter M, Nothacker M, Oettle H, Post S, Reinacher-Schick A, Röcken C, Roeb E, Saeger H, Schmid R, Schmiegel W, Schoenberg M, Siveke J, Stuschke M, Tannapfel A, Uhl W, Unverzagt S, van Oorschot B, Vashist Y, Werner J, Yekebas E; Guidelines Programme Oncology AWMF; German Cancer Society eV; German Cancer Aid.

Z Gastroenterol. 2013 Dec;51(12):1395-440. doi: 10.1055/s-0033-1356220. Epub 2013 Dec 11. German. No abstract available.

35.

Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group.

Giessen C, Graeven U, Laubender RP, Modest DP, Schulz C, Porschen R, Schmiegel W, Reinacher-Schick A, Hegewisch-Becker S, Stintzing S, Heinemann V.

Ann Oncol. 2013 Dec;24(12):3051-5. doi: 10.1093/annonc/mdt402. Epub 2013 Oct 14.

PMID:
24130263
36.

Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study.

Stein A, Arnold D, Thuss-Patience PC, Moehler M, Grothe W, Seufferlein T, Reinacher-Schick A, Geissler M, Hofheinz RD, Schmoll HJ.

Acta Oncol. 2014 Mar;53(3):392-8. doi: 10.3109/0284186X.2013.833346. Epub 2013 Sep 12.

PMID:
24024696
37.

[S3-guideline colorectal cancer version 1.0].

Pox C, Aretz S, Bischoff SC, Graeven U, Hass M, Heußner P, Hohenberger W, Holstege A, Hübner J, Kolligs F, Kreis M, Lux P, Ockenga J, Porschen R, Post S, Rahner N, Reinacher-Schick A, Riemann JF, Sauer R, Sieg A, Scheppach W, Schmitt W, Schmoll HJ, Schulmann K, Tannapfel A, Schmiegel W; Leitlinienprogramm Onkologie der AWMF; Deutschen Krebsgesellschaft e. V; Deutschen Krebshilfe e. V.

Z Gastroenterol. 2013 Aug;51(8):753-854. doi: 10.1055/s-0033-1350264. Epub 2013 Aug 16. German. No abstract available.

38.

ß-Catenin, Cox-2 and p53 immunostaining in colorectal adenomas to predict recurrence after endoscopic polypectomy.

Brand L, Munding J, Pox CP, Ziebarth W, Reiser M, Hüppe D, Schmiegel W, Reinacher-Schick A, Tannapfel A.

Int J Colorectal Dis. 2013 Aug;28(8):1091-8. doi: 10.1007/s00384-013-1667-z. Epub 2013 Mar 21.

PMID:
23516071
39.

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.

Schmiegel W, Reinacher-Schick A, Arnold D, Kubicka S, Freier W, Dietrich G, Geißler M, Hegewisch-Becker S, Tannapfel A, Pohl M, Hinke A, Schmoll HJ, Graeven U.

Ann Oncol. 2013 Jun;24(6):1580-7. doi: 10.1093/annonc/mdt028. Epub 2013 Mar 4.

PMID:
23463625
40.

[Colorectal carcinoma: what's new?].

Pox C, Schmiegel W, Reinacher-Schick A.

Dtsch Med Wochenschr. 2012 Dec;137(49):2577-80. doi: 10.1055/s-0032-1327268. Epub 2012 Nov 27. Review. German. No abstract available.

PMID:
23188639
41.

Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma.

Baraniskin A, Nöpel-Dünnebacke S, Ahrens M, Jensen SG, Zöllner H, Maghnouj A, Wos A, Mayerle J, Munding J, Kost D, Reinacher-Schick A, Liffers S, Schroers R, Chromik AM, Meyer HE, Uhl W, Klein-Scory S, Weiss FU, Stephan C, Schwarte-Waldhoff I, Lerch MM, Tannapfel A, Schmiegel W, Andersen CL, Hahn SA.

Int J Cancer. 2013 Jan 15;132(2):E48-57. doi: 10.1002/ijc.27791. Epub 2012 Sep 14.

42.

Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group.

Reinacher-Schick A, Schulmann K, Modest DP, Bruns N, Graeven U, Jaworska M, Greil R, Porschen R, Arnold D, Schmiegel W, Tannapfel A.

BMC Cancer. 2012 Aug 9;12:349. doi: 10.1186/1471-2407-12-349.

43.

Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.

Modest DP, Reinacher-Schick A, Stintzing S, Giessen C, Tannapfel A, Laubender RP, Brodowicz T, Knittelfelder R, Vrbanec D, Schmiegel W, Heinemann V, Zielinski CC.

Anticancer Drugs. 2012 Jul;23(6):666-73. doi: 10.1097/CAD.0b013e328352ff1d.

PMID:
22441566
44.

Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer.

Harder J, Ihorst G, Heinemann V, Hofheinz R, Moehler M, Buechler P, Kloeppel G, Röcken C, Bitzer M, Boeck S, Endlicher E, Reinacher-Schick A, Schmoor C, Geissler M.

Br J Cancer. 2012 Mar 13;106(6):1033-8. doi: 10.1038/bjc.2012.18. Epub 2012 Feb 28.

45.

MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL.

Baraniskin A, Birkenkamp-Demtroder K, Maghnouj A, Zöllner H, Munding J, Klein-Scory S, Reinacher-Schick A, Schwarte-Waldhoff I, Schmiegel W, Hahn SA.

Carcinogenesis. 2012 Apr;33(4):732-9. doi: 10.1093/carcin/bgs020. Epub 2012 Jan 27.

PMID:
22287560
46.

TFAP2E-DKK4 and chemoresistance in colorectal cancer.

Ebert MP, Tänzer M, Balluff B, Burgermeister E, Kretzschmar AK, Hughes DJ, Tetzner R, Lofton-Day C, Rosenberg R, Reinacher-Schick AC, Schulmann K, Tannapfel A, Hofheinz R, Röcken C, Keller G, Langer R, Specht K, Porschen R, Stöhlmacher-Williams J, Schuster T, Ströbel P, Schmid RM.

N Engl J Med. 2012 Jan 5;366(1):44-53. doi: 10.1056/NEJMoa1009473.

47.

The influence of 5-aminosalicylic acid on the progression of colorectal adenomas via the β-catenin signaling pathway.

Munding J, Ziebarth W, Pox CP, Ladigan S, Reiser M, Hüppe D, Brand L, Schmiegel W, Tannapfel A, Reinacher-Schick AC.

Carcinogenesis. 2012 Mar;33(3):637-43. doi: 10.1093/carcin/bgr306. Epub 2011 Dec 22.

PMID:
22198215
48.

[Chemotherapy-associated steatohepatitis in patients with colorectal cancer and surgery on hepatic metastasis: clinical validation of a histopathological scoring system and preoperative risk assessment].

Kampfenkel T, Tischoff I, Bonhag H, Eckardt M, Schmiegel W, Tannapfel A, Reinacher-Schick A, Viebahn R.

Z Gastroenterol. 2011 Oct;49(10):1407-11. doi: 10.1055/s-0031-1281749. Epub 2011 Sep 30. German.

PMID:
21964894
49.

Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.

Pohl M, Werner N, Munding J, Tannapfel A, Graeven U, Nickenig G, Schmiegel W, Reinacher-Schick A.

Z Gastroenterol. 2011 Oct;49(10):1398-406. doi: 10.1055/s-0031-1281752. Epub 2011 Sep 30. Review.

PMID:
21964893
50.

[Special edition gastrointestinal oncology 2011].

Reinacher-Schick A.

Z Gastroenterol. 2011 Oct;49(10):1395. doi: 10.1055/s-0031-1273482. Epub 2011 Sep 30. German. No abstract available.

PMID:
21964891

Supplemental Content

Loading ...
Support Center